Alterations in platelet activity and endothelial glycocalyx biomarkers by treatment with an angiotensin converting enzyme inhibitor or an alpha-1 adrenoceptor antagonist in patients with hypertension: results from the DoRa study
| Autor: | Mikael Ekholm, Andreas Jekell, Kristina Lundwall, Joakim Alfredsson, Tomas L Lindahl, Håkan Wallén, Thomas Kahan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Platelets, Vol 35, Iss 1 (2024) |
| Druh dokumentu: | article |
| ISSN: | 09537104 1369-1635 0953-7104 |
| DOI: | 10.1080/09537104.2024.2437768 |
| Popis: | Drugs blocking the renin–angiotensin–aldosterone system may offer benefit on endothelial function, inflammation, and hemostasis in addition to the effects of reducing blood pressure. We have shown antithrombin effects by treatment with the angiotensin converting enzyme (ACE) inhibitor ramipril. As thrombin is a key inducer of platelet aggregation, we hypothesized that treatment with ramipril could modulate platelet reactivity and endothelial glycocalyx (eGCX) function. This study assessed platelet activity (CD40 ligand and P-selectin) and eGCX markers (E-selectin, hyaluronan, syndecan-1, and thrombomodulin) in 59 individuals with mild-to-moderate hypertension, randomized double-blind to ramipril 10 mg or doxazosin 8 mg od for 12 weeks. Ramipril and doxazosin similarly reduced blood pressure. Antihypertensive treatment reduced CD40 ligand (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|